A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection

Journal of Clinical Microbiology

Volumn 50, Issue 3, 2012, Pages 831-836

  Gueudin, Marie ^a,b   Leoz, Marie ^a,b   Lemée, Véronique ^a   De Oliveira, Fabienne ^a   Vessière, Aurélia ^c   Kfutwah, Anfumbom ^c   Plantier, Jean Christophe ^a,b  

^a HÔPITAL CHARLES NICOLLE   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c CENTRE PASTEUR DU CAMEROUN   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE DOSAGE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP M; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP O; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP P; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTEGRASE O RNA ASSAY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LONG TERMINAL REPEAT; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION; VIRUS EXAMINATION; VIRUS IDENTIFICATION; VIRUS STRAIN;

GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 84857377916     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05669-11     Document Type: Article

References (33)

1. Agut H, et al. 1992. Isolation of atypical HIV-1-related retrovirus from AIDS patient. Lancet 340:681-682.
2. Ayouba A, et al. 2001. HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg. Infect. Dis. 7:466-467.
3. Brand D, et al. 2004. First identification of HIV-1 groups M and O dual infections in Europe. AIDS 18:2425-2428. (Pubitemid 40065910)
4. Chaix-Baudier ML, et al. 1998. First case of mother-to-infant HIV type 1 group O transmission and evolution of C2V3 sequences in the infected child. French HIV Pediatric Cohort Study Group. AIDS Res. Hum. Retroviruses 14:15-23.
5. Depatureaux A, et al. 2010. Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide. Antimicrob. Agents Chemother. 54:4016-4019.
6. Depatureaux A, et al. 2011. Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. J. Acquir. Immune Defic. Syndr. 56:139 -145.
7. Depatureaux A, et al. 19 June 2010, posting date. Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data. Med. Mal. Infect. [Epub ahead of print.] doi:10.1016/j.medmal.2010.04.011. (In French.)
8. Descamps D, et al. 1997. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J. Virol. 71:8893-8898. (Pubitemid 27446478)
9. Gueudin M, et al. 2004. Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O. J. Acquir. Immune Defic. Syndr. 36:639-641. (Pubitemid 38544515)
10. Gueudin M, et al. 2003. Plasma viral RNA assay in HIV-1 group O infection by real-time PCR. J. Virol. Methods 113:43- 49.
11. Gueudin M, et al. 2007. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 44:500-505. (Pubitemid 46594892)
12. Hampl H, et al. 1995. First case of HIV-1 subtype 0 infection in Germany. Infection 23:369-370. (Pubitemid 26007908)
13. Leoz M, et al. 2008. Integrase polymorphism and HIV-1 group O diversity. AIDS 22:1239-1243.
14. Loussert-Ajaka I, et al. 1995. Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J. Virol. 69:5640 -5649.
15. Plantier JC, et al. 2005. HIV-1 resistance genotyping on dried serum spots. AIDS 19:391-397.
16. Plantier JC, et al. 2009. Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. J. Clin. Microbiol. 47:2906-2911.
17. Plantier JC, et al. 2004. HIV-1 group M superinfection in an HIV-1 group O-infected patient. AIDS 18:2444-2446.
18. Plantier JC, et al. 2009. A new human immunodeficiency virus derived from gorillas. Nat. Med. 15:871- 872.
19. Quinones-Mateu ME, Soriano V, Domingo E, Menendez-Arias L. 1997. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology 236:364-373. (Pubitemid 27423779)
20. Rayfield MA, et al. 1996. HIV-1 group O virus identified for the first time in the United States. Emerg. Infect. Dis. 2:209-212.
21. Roques P, et al. 2002. Phylogenetic analysis of 49 newly derived HIV-1 group O strains: high viral diversity but no group M-like subtype structure. Virology 302:259 -273.
22. Simon F, et al. 2001. Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res. Hum. Retroviruses 17:937-952. (Pubitemid 32881336)
23. Sire JM, et al. 2011. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays. J. Acquir. Immune Defic. Syndr. 56:239 -243.
24. Soriano V, et al. 1996. First case of HIV-1 group O infection in Spain. Vox Sang. 71:66.
25. Sullivan PS, et al. 2000. Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States. J. Infect. Dis. 181:463-469. (Pubitemid 30131811)
26. Swanson P, et al. 2005. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J. Clin. Microbiol. 43:3860-3868. (Pubitemid 41129673)
27. Tuaillon E, et al. 2004. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J. Acquir. Immune Defic. Syndr. 37:1543-1549. (Pubitemid 39658189)
28. Vallari A, et al. 2011. Confirmation of putative HIV-1 group P in Cameroon. J. Virol. 85:1403-1407.
29. Vergne L, et al. 2003. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02-AG variant and disease stage. Virology 310:254 -266.
30. Vessiere A, et al. 2011. HIV-1 M/O dual infections and recombinant forms circulating in Cameroon and France, poster B125. Abstr. 18th Conf. Retroviruses Oppor. Infect., Boston, MA.
31. Vessiere A, et al. 2010. First evidence of a HIV-1 M/O recombinant form circulating outside Cameroon. AIDS 24:1079 -1082.
32. Vessiere A, et al. 2010. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J. Acquir. Immune Defic. Syndr. 53:107-110.
33. Yamaguchi J, et al. 2004. HIV infections in northwestern Cameroon: identification of HIV type 1 group O and dual HIV type 1 group M and group O infections. AIDS Res. Hum. Retroviruses 20:944-957. (Pubitemid 39369701)